

One simple solution for managing chronic kidney disease* and hypertension



Management made easier


Semintra® 4 mg/ml Oral Solution for Cats is now indicated for both **chronic kidney disease (CKD)*** and **hypertension**, offering more **flexibility** for you and your clients

- Unique mode of action that blocks the harmful effects of the RAAS but not the beneficial effects**
- **Easy-to-use dosing and bottle duration charts** are available overleaf



Easy-to-give and accurate dosing

- New **ml-calibrated** syringe helps to ensure accurate dosing and allows for dose alterations in patients with hypertension (HT)
- Easy to Give™ Approved by iCatCare
- Well accepted by over 90% of cats and owners²



Improving client experience

Packaging includes a QR code that links to online **pet owner resources**

- Encourages **pet owner compliance** with easy-to-follow **'How to use' video**
- **Downloadable product information sheet**
- New packaging will continue to **include a printed product information leaflet** for pet owners who prefer a hard copy



Semintra® 4 mg/ml provides convenient once-daily dosing for CKD* and/or HT†



	Body weight (kg)							
	1	2	3	4	5	6	7	8
	Dose (ml/day)							
CKD* 1 mg/kg dose	0.25	0.5	0.75	1.0	1.25	1.5	1.75	2.0
HT +/- CKD* 2 mg/kg dose	0.5	1.0	1.5	2.0	2.5	3.0	3.5	4.0



Semintra® 4 mg/ml bottle duration†

Bottle size	Body weight (kg)							
	1	2	3	4	5	6	7	8
	Approximate number of days							
30 ml for CKD*	120	60	40	30	24	20	17	15
30 ml for HT +/- CKD*	60	30	20	15	12	10	8	7
100 ml for CKD*	400	200	133	100	80	66	57	50
100 ml for HT +/- CKD*	200	100	66	50	40	33	28	25



Please contact Veterinary Technical Services on 01344 746957 or vetenquiries@boehringer-ingelheim.com if you have any questions about using Semintra®, one simple solution for managing CKD* and hypertension

*Semintra® is licensed for the reduction of proteinuria associated with chronic kidney disease in cats and for the treatment of systemic hypertension in cats

**Renin-Angiotensin-Aldosterone System

†Dosing guidelines: when treating concomitant CKD and HT, dose according to the HT dose. After 4 weeks, the dosage of telmisartan may be reduced in cats with systolic blood pressure (SBP) of less than 140 mmHg (in 0.5 mg/kg increments) at the discretion of the veterinary surgeon. If SBP increases over the course of the disease, the daily dose may be increased again up to 2 mg/kg. Target SBP range is between 120 and 140 mmHg. The recommended minimum effective dose when treating concomitant CKD and HT is 1 mg/kg

References: 1. Summary of Product Characteristics (SPC): Semintra® (telmisartan). European Medicines Agency. 2. Zimmering T. Ease of use of Semintra® and its effects on quality of life – update on cat owner feedback ("EASY Programme"). In: Federation of European Companion Animal Veterinary Association (FECAVA) Congress Barcelona, Spain



Semintra® contains telmisartan. UK: POM-V IE: POM. Prescription decisions are for the person issuing the prescription alone. Further information available in the SPC or from Boehringer Ingelheim Animal Health UK Ltd. RG12 8YS, UK. UK Tel: 01344 746959 (sales) or 01344 746957 (technical), IE Tel: 01 291 3985 (all queries).

Email: vetenquiries@boehringer-ingelheim.com. Semintra® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under licence. ©2025 Boehringer Ingelheim Animal Health UK Ltd. All rights reserved. Date of preparation: Feb 2025. UI-PHC-XXXX-2025. Use Medicines Responsibly.